Case study on Glibenclamide

Glibenclamide or glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM)
It was discovered in 1969 and approved for medical use in the united states in 1984.
Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.
Drug Class : Hypoglycemics ;Sulfonylureas
Indications : Diabetes mellitus, type 2
SIDE EFFECTS : Hypoglycemia, Angioedema, Weight gain etc.

1. Project Report On glibenclamide JAMIA HAMDARD Pharmaceutical Management SUBMITTED TO : MR. UBADA AQEEL SUBMITTED BY : MD. FAHEEM KHAN NITESH SHARMA NITESH SHRIVASTAV PRAGYA TIWARI PRAVEEN MISHRA

2. GLIBENCLAMIDE Glibenclamide or glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM ) It was discovered in 1969 and approved for medical use in the united states in 1984. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release . Drug Class : Hypoglycemics ; Sulfonylureas Indications : Diabetes mellitus, type 2 SIDE EFFECTS : Hypoglycemia, Angioedema , Weight gain etc.

3. MECHANISM OF ACTION The mechanism action of drug consists in the inhibition of the ATP sensitive K+ channel which lead to the depolarisation of the cells and insulin secretion.

4. OBJECTIVE The primary objective of this project is : * To find knowledge for the different top brands of GLIBENCLAMIDE. * To know about the number of prescriptions per week. * Doctors who prescribed it. * Reason for prescribing the drug of particular brand.

5. Market research on glibenclamide Glibenclamide is the research molecule of Boehringer Mannheim (now part of Roche) and Hoechst (now part of sanofi ) It is a poor man drug. Glibenclamide was once on the top of the ladder for the choice of drug in the class of sulphonylureas . With the time glibenclamide could not compete with the other competitors of the class sulphonylureas like glimipride , glipizide etc. Many popular brands like Daonil which once ruled the market are now rarely prescribed. One of the most potent anti-diabetic drug just ruled out of the market because of its side effects like hypoglycemia, angioedema , etc.

6. SR.NO BRAND NAME COMAPANY COMPOSITION NO.OF PRESCRIPTION/MONTH 1 DAONIL TAB SANOFI GLIBENCLAMIDE 15-20 2 GLINIL TAB CIPLA GLIBENCLAMIDE 14-17 3 EUGLUC-ON ABBOT GLIBENCLAMIDE 10-12 4 DIABETROL ABBOT GLIBENCLAMIDE + METFORMIN 8-10 5 GLYBORAL USV GLIBENCLAMIDE 5-8 YEAR (2015-2017)

7. YEAR (2018- 2019) SR.NO BRAND NAME COMPANY COMPOSITION NO.OF PRESCRIPTION/MONTH 1 DAONIL TAB SANOFI GLIBENCLAMIDE 1-2 2 GLINIL TAB CIPLA GLIBENCLAMIDE 0-1 3 EUGLUC-ON ABBOT GLIBENCLAMIDE 4 DIABETROL ABBOT GLIBENCLAMIDE + METFORMIN 1-2 5 GLYBORAL USV GLIBENCLAMIDE

8. Source of data collection

9. Fall Down Of Glibenclamide Epidermiological suggest that the administration of of Glibenclamide is associated with an increased risk of cardivascular mortality,compared to treatment with Metformin or Gliclazide . Cause moderate to severe lowering of blood glucose level. Cause mild to moderate weight gain on consumption. Cause hemolytic anaemia if one have a rare genetic disorder called G6PD defficiency .

10. Visited doctors DR. KRISHNA VISHWAS ( HOD) ENDROCRIONOLOGY, SAFADARJUNG HOSPITAL DR. AJAY KUMAR AJMANI APOLLO PHARMACY DR. AKHILESH KUMAR BINDA POLYCLINIC

11. LEARNING * On different brands of Glibenclamide availability across stores in delhi . * Field work is more effective than theoretical knowledge alone. * Reinforced with the knowledge that the drug Glibenclamide is prescribed in least number from last two years. OBSTACLES * Rejection from some of the chemist and doctors. * Due to lack of time doctors and chemist refused to give information. * Several chemist shop closed for long lunch breaks on working days

12. conclusion Glibenclamide should be used with caution especially in geriatic population . Specific characteristics, including renal insufficiency and advancing age may predispose patients to the development of drug-induced hypoglycaemia . Patient evaluation is critical in identifying patients at greatest risk and in preventing complications. Top brand of glibenclamide was Daonil M – Glibenclamide and metformin hydrocholoride , Sanofi Aventis Pharma India Total number of prescription per month was 1 to 2 or nill. Reason for prescribing Daonil is that it is not addictive.